deferiprone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4188	30652-11-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: deferiprone deferione ferriprox	a chelating agent with an affinity for ferric ion (iron III) indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes Molecular weight: 139.15 Formula: C7H9NO2 CLOGP: -0.90 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 40.54 ALOGS: 0.29 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 25, 1999	EMA	APOTEX EUROPE BV
Oct. 14, 2011	FDA	APOPHARMA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	264.31	34.48	65	894	23684	53324423
Sickle cell anaemia with crisis	153.81	34.48	31	928	4496	53343611
Neutropenia	80.01	34.48	44	915	159141	53188966
Serum ferritin increased	60.37	34.48	15	944	5549	53342558
Death	34.71	34.48	37	922	357195	52990912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	156.73	30.35	46	763	23431	32489286
Neutropenia	56.50	30.35	38	771	142137	32370580
Sickle cell anaemia with crisis	45.60	30.35	11	798	2598	32510119
Death	45.23	30.35	51	758	382466	32130251
Serum ferritin increased	32.13	30.35	10	799	6069	32506648

Pharmacologic Action:

Source	Code	Description
ATC	V03AC02	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Iron chelating agents
FDA MoA	N0000000144	Iron Chelating Activity
FDA EPC	N0000175522	Iron Chelator
MeSH PA	D002614	Chelating Agents
MeSH PA	D007502	Iron Chelating Agents
MeSH PA	D064449	Sequestering Agents
CHEBI has role	CHEBI:38157	iron chelators
CHEBI has role	CHEBI:50267	protective agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Iron overload	indication	60737008
beta Thalassemia	indication	65959000	DOID:12241

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.54	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	8703156	Oct. 26, 2029	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	8703156	Oct. 26, 2029	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	10780055	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	10940115	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1GM	FERRIPROX	CHIESI	N021825	July 25, 2019	RX	TABLET	ORAL	April 30, 2024	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
500MG	FERRIPROX	CHIESI	N021825	Oct. 14, 2011	RX	TABLET	ORAL	April 30, 2024	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	April 30, 2024	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	April 30, 2024	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	April 30, 2024	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Deoxyhypusine hydroxylase	Enzyme	Q9BU89	DOHH_HUMAN		IC50	5.30		CHEMBL

External reference:

ID	Source
4031179	VUID
N0000183921	NUI
D07416	KEGG_DRUG
4031179	VANDF
C0043832	UMLSCUI
CHEBI:68554	CHEBI
CHEMBL70927	ChEMBL_ID
D000077543	MESH_DESCRIPTOR_UI
DB08826	DRUGBANK_ID
7456	IUPHAR_LIGAND_ID
6958	INN_ID
2BTY8KH53L	UNII
2972	PUBCHEM_CID
11645	RXNORM
117386	MMSL
18035	MMSL
51626	MMSL
d04976	MMSL
007561	NDDF
329482000	SNOMEDCT_US
396011004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0576	TABLET, COATED	500 mg	ORAL	ANDA	28 sections
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0711	TABLET, COATED	1000 mg	ORAL	ANDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-100	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-100	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-101	SOLUTION	100 mg	ORAL	NDA	29 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-103	TABLET, FILM COATED	1000 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-104	TABLET	1000 mg	ORAL	NDA	28 sections
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4196	TABLET	500 mg	ORAL	ANDA	31 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	52609-0006	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	52609-0007	TABLET, FILM COATED	1000 mg	ORAL	NDA	29 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	52609-4502	SOLUTION	100 mg	ORAL	NDA	29 sections